Apart from its impact on muscle mass, FST gene therapy has been proved to prevent HFD-induced obesity and completely normalize muscle glucose uptake in diet-induced insulin-resistant obese mice. This evidence concerns the gene FST and obesity due to melanocortin 4 receptor deficiency.